A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease

Exclusion Criteria

• •The participant has a decreased best-corrected visual acuity due to optic neuropathy, defined as a decrease in vision of 2 lines on the Snellen chart, new visual field defect, or colour defect secondary to optic nerve involvement, within 6 months prior to the Screening Visit.
• •The participant has corneal decompensation unresponsive to medical management.
• •The participant has a decrease in proptosis of ≥2 mm between the Screening Visit and the Baseline Visit.
• •The participant has a decrease in CAS of ≥2 points between the Screening Visit and the Baseline Visit.
• •The participant has had previous orbital irradiation or surgery for TED.
• •The participant requires immediate surgical ophthalmological intervention or has other eye conditions impacting the assessments.
• •The participant has contraindications for an magnetic resonance imaging (MRI) scan.
• •The participant has an active infection at Baseline or recent serious infection (for example, requiring hospitalization) within 8 weeks prior to the Baseline Visit.
• •The participant takes any of the following disallowed or restricted concomitant medications (the list is not comprehensive):
• •Disallowed: any investigational products within 30 days or 5 half-lives, whichever is longer, prior to the Screening Visit, systemic corticosteroids within 6 weeks prior to the Screening Visit (topical steroids for dermatological conditions, inhaled or intranasal steroids are allowed), systemic immunosuppressive/immunomodulating drugs (for example, rituximab, tocilizumab, methotrexate, cyclosporine, azathioprine, mycophenolate-sodium/mofetil, Janus kinase inhibitors) within 5 half-lives prior to the Screening Visit, live attenuated vaccines within 30 days prior to the Baseline Visit, biotin within 1 day prior to the Screening Visit.
• •Allowed with restriction: stable dose for \>3 weeks prior to the Screening Visit of selenium. Inactivated/killed/RNA-based vaccinations are allowed provided they are not administered within 5 days before/after any investigational medicinal product (IMP) trial visits.